Trading Paradigm

Engineer Consistent Trading Results With Proper Perspectives & Behaviors

  • Home
  • About
  • Reviews
    • Trading Composure
    • Trading in the Zone
  • Quotes
  • #1 Reason 90% of Traders Fail and How You Can Avoid Being One of Them

What is a Complete Response Letter (CRL)?

April 18, 2017 By Matt Thomas Leave a Comment


Biotech Terminology – Complete Response Letter (CRL):

A Complete Response Letter (CRL) lets the drug sponsor know that their New Drug Application (NDA) has been reviewed and cannot be accepted in its present form. The letter cites specific deficiencies and outlines recommended actions for getting the application prepared for approval.

Complete Response Letters are typically bad news since it means the drug hasn’t been accepted yet, but it’s not necessarily rejected either. The drug sponsors still have an opportunity to correct the shortcomings and resubmit. It’s important to note that CLR’s are not made public by the Food and Drug Administration (FDA), allowing the drug-developing company to disclose as little or as much of the information contained within it as they would like. This can become problematic for traders and investors alike, leaving them to wonder whether or not their investment has lost substantial value once a CRL has been issued.

Related Page: What is BioTech Breakouts? Capture Explosive Gains in Biotech Stocks

Filed Under: The Daily Dose: Thought-Provoking Questions For Stock Traders

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Privacy Policy||Disclaimer||Site Map||Contact||About